Institute of Hematology & Blood Diseases Hospital, China: all 402 studies

Page 3 of 5. Open to participants first (296), then studies with results posted, then the rest; newest registration first within each.

• The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 MutationRecruitingNCT06561880Phase 1/2
• Thalidomide for the Symptomatic Large Granular Lymphocytic LeukemiaRecruitingNCT06530576Phase 2
• PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell LymphomasRecruitingNCT06530550Phase 2
• Intermediate-dose HAD Regimen for CEBPA Double-mutated AMLRecruitingNCT06529250Not applicable
• Comparison of Different Dose of Anti-T Lymphocyte Globulin (ATLG) in Haploidentical HSCT for GVHD ProphylaxisNot yet recruitingNCT06525519Phase 3
• Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone LymphomasRecruitingNCT06513234Phase 2
• The Use of Blinatumomab in Patients With NGS-MRD Relapsed B-ALL After Autologous/Allogeneic TransplantationNot yet recruitingNCT06504186Not applicable
• Low-dose Cyclophosphamide or CNI in the Prevention of Acute Graft-versus-host Disease After gDLINot yet recruitingNCT06490562Not applicable
• An Epidemiological Study to Investigate the Characteristics of RSV Infection in Adult Hematopoietic Cell Transplant Recipients or Hematological Malignancies Patients in Tianjin HI (Hematology Institute)RecruitingNCT06490549
• Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCLRecruitingNCT06489808Phase 2
• Prospective Observational Clinical Study on Changes in Cognitive Levels in Elderly Patients Before and After Hematopoietic Stem Cell TransplantationNot yet recruitingNCT06484049
• Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALLRecruitingNCT06481241Not applicable
• Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALLRecruitingNCT06481228Not applicable
• Combination of Steroid and Humanized CD25 Monoclonal Antibody as First-line Therapy for aGVHDNot yet recruitingNCT06473909Phase 2
• the Efficacy and Safety of Total Myeloid Irradiation (TMI) in the Treatment of Adult Acute Lymphoblastic LeukemiaNot yet recruitingNCT06461091
• VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCTRecruitingNCT06447090Phase 2
• Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic LeukemiaRecruitingNCT06427330Phase 2
• Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell LymphomaRecruitingNCT06415708Phase 2
• Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALLRecruitingNCT06387121Phase 2
• Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid LeukemiaRecruitingNCT06386302Not applicable
• MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLLNot yet recruitingNCT06367374Phase 2
• Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple MyelomaRecruitingNCT06302699
• Avatrombopag in the Treatment of Pediatric Immune ThrombocytopeniaRecruitingNCT06281327Phase 2
• Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaRecruitingNCT06265545Not applicable
• Rituximab for Serious Aplastic Anemia With Platelet Transfusion RefractorinessRecruitingNCT06254560Phase 2
• Efficacy and Safety of Avatrombopag vs. Avatrombopag Combined With rhTPO in the Treatment of SAANot yet recruitingNCT06254287Phase 2
• GVM±R in Patients With Relapsed or Refractory Aggressive NHL.RecruitingNCT06244368Phase 2
• Safety and Efficacy Study of NGGT003 in Hemophilia A PatientsRecruitingNCT06238908Early Phase 1
• Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic LeukemiaRecruitingNCT06224257Phase 2
• Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia PatientsRecruitingNCT06219239Not applicable
• CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of TherapyRecruitingNCT06212154Phase 1
• Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.RecruitingNCT06208137Not applicable
• Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)RecruitingNCT06168851Phase 2
• DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple MyelomaRecruitingNCT06158269Phase 2
• Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AMLNot yet recruitingNCT06133556Phase 2
• Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)RecruitingNCT06107582
• Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic MicroangiopathyRecruitingNCT06102694
• A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)RecruitingNCT06094881Phase 2
• A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma PatientsNot yet recruitingNCT06087419Phase 1/2
• Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem CellsRecruitingNCT06041620Not applicable
• The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic AnemiaRecruitingNCT06021977Phase 2
• Anti-CD38 Antibody Treating Evans SyndromeRecruitingNCT06014775Phase 2
• A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune ThrombocytopeniaRecruitingNCT05995054Phase 2
• Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene TherapyRecruitingNCT05991336
• Anti-CD38 Antibody Treating APS With ThrombocytopeniaRecruitingNCT05983952Phase 2
• A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell LeukemiaRecruitingNCT05979363Phase 2
• Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell LymphomaRecruitingNCT05958719Phase 2
• The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic SyndromesRecruitingNCT05925504Phase 2
• Humanized Anti-CD25 Antibody for Prophylaxis of aGVHD in Elderly Underwent HID-HSCTNot yet recruitingNCT05923814Phase 2
• Ruxolitinib as GVHD Prophylaxis in AA PatientsNot yet recruitingNCT05914714Phase 2
• Secondary Prophylaxis of CMV Infection Using Letermovir After HID-HSCTNot yet recruitingNCT05914701Phase 4
• Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCTNot yet recruitingNCT05914675Phase 4
• Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WMRecruitingNCT05914662Phase 2
• YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple MyelomaRecruitingNCT05913804Phase 1
• A Study to Evaluate the Safety and Efficacy of COVID-19 Convalescent Plasma (CCP) Transfusion to Prevent COVID-19 in Adult Recipients Following Hematopoietic Stem Cell TransplantationRecruitingNCT05904067Not applicable
• ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer InhibitorRecruitingNCT05888870Phase 4
• Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PVRecruitingNCT05870475Phase 2
• An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia ARecruitingNCT05849740Phase 4
• Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World StudyRecruitingNCT05846763
• Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone LymphomaRecruitingNCT05846750Phase 2
• TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)RecruitingNCT05718856Phase 4
• Gene Therapy for Hemophilia B Patients Aged 12-18 Years OldRecruitingNCT05709288Phase 1
• Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic LeukemiaRecruitingNCT05660473Phase 2
• A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B PatientsRecruitingNCT05641610Phase 1/2
• ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)RecruitingNCT05632380Phase 1/2
• The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.RecruitingNCT05630651Not applicable
• Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT ModelRecruitingNCT05599256Phase 2
• ctDNA Methylation Sequencing for MyelomaRecruitingNCT05578625
• The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients.RecruitingNCT05523128Not applicable
• Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid LeukemiaRecruitingNCT05519384Early Phase 1
• The Safety and Efficacy Study of Avatrombopag Switch in TPO-RA Refractory AARecruitingNCT05518331Not applicable
• Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALLRecruitingNCT05495035Phase 1
• A Study of FVIII Gene Therapy for Hemophilia ARecruitingNCT05454774Early Phase 1
• Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential ThrombocythemiaRecruitingNCT05395507Phase 2
• Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and LymphomaRecruitingNCT05294055Phase 2
• Herombopag for Chemotherapy-induced ThrombocytopeniaRecruitingNCT05236582Phase 2
• Avatrombopag for Chemotherapy-induced ThrombocytopeniaRecruitingNCT05218226Phase 2
• A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune ThrombocytopeniaRecruitingNCT05214391Phase 2
• Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary ThrombocytopeniaRecruitingNCT05199909Phase 2
• Safety and Tolerability of VGB-R04 in Patients With Haemophilia BRecruitingNCT05152732Early Phase 1
• Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With AutoantibodiesRecruitingNCT04993885Phase 2
• R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLLNot yet recruitingNCT04992377Phase 2
• TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With AutoantibodiesRecruitingNCT04915482Phase 2/3
• TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 YearsRecruitingNCT04890041Not applicable
• Gene Therapy for Chinese Hemophilia ARecruitingNCT04728841Not applicable
• Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.RecruitingNCT04688736Phase 2
• National Longitudinal Cohort of Hematological DiseasesRecruitingNCT04645199
• Eltrombopag for Chemotherapy-induced ThrombocytopeniaRecruitingNCT04600960Phase 2
• Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in AdultsRecruitingNCT04518475Phase 4
• TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLLRecruitingNCT04453345Phase 2/3
• Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous LineageRecruitingNCT04440267Phase 2
• Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential ThrombocythemiaRecruitingNCT04226950Phase 2
• A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological MalignanciesAvailableNCT04008524
• Evaluation of Immune Status Before and After Splenectomy in Immune Thrombocytopenia PatientsRecruitingNCT03998059
• A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLLRecruitingNCT03980002Phase 2
• Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid LeukemiaEnrolling by invitationNCT03031249Phase 1/2
• Clinical Study of UC-MSC Combined With Immunosuppressive Agents in the Treatment of Pediatric HAAACompletedNCT07850362Not applicable
• CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT07809594Phase 1
• Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic LeukemiaWithdrawnNCT07585734Phase 1/2
• EPOCH-Economics and Patient Outcomes in China in HaemophiliaActive, not recruitingNCT07454239

← Institute of Hematology & Blood Diseases Hospital, China overview and focus areas